Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Jan 28;11(1):2594.
doi: 10.1038/s41598-021-82296-z.

Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia

Collaborators, Affiliations
Clinical Trial

Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia

Irene Motta et al. Sci Rep. .

Abstract

Hematologists are frequently involved in the diagnostic pathway of Gaucher disease type 1 (GD1) patients since they present several hematological signs. However, GD1 is mainly underdiagnosed because of a lack of awareness. In this multicenter study, we combine the use of a diagnostic algorithm with a simple test (β-glucosidase activity on Dried Blood Spot) in order to facilitate the diagnosis in a population presenting to the hematologist with splenomegaly and/or thrombocytopenia associated with other hematological signs. In this high-risk population, the prevalence of GD1 is 3.3%. We propose an equation that predicts the probability of having GD1 according to three parameters that are routinely evaluated: platelet count, ferritin, and transferrin saturation.

PubMed Disclaimer

Conflict of interest statement

IM received Lecture Honoraria from Sanofi Genzyme and is a member of Sanofi Genzyme advisory board. WB is a member of Agios, Alexion, Apellis, Biocryst, Bioverativ, Incyte, Momenta, Novartis advisory board, received lecture honoraria from Alexion, Incyte, Novartis, Sanofi and research support from Alexion. MDC is a member of Vifor, Sanofi Genzyme, Celgene, Novartis, and Bluebird advisory board. DC, MS, CB, EC, BT, PR, LB, LF, AP, FL, MF have no conflict of interest.

Figures

Figure 1
Figure 1
Results of DBS, β‐glucosidase assay in cell homogenate, and molecular analysis of the enrolled patients. DBS dried blood spot, GD1 Gaucher disease type 1. *They did not fulfill the inclusion and exclusion criteria.
Figure 2
Figure 2
Receiver operating characteristic (ROC) curves of GD1 for platelets (thousands/mm3), ferritin (μg/L), transferrin saturation (%), and for the three variables jointly analyzed in a multiple logistic regression model. AUC area under the curve, CI confidence interval.

References

    1. Charrow J, et al. The Gaucher registry: Demographics and disease characteristics of 1698 patients with Gaucher disease. Arch. Intern. Med. 2000;160:2835–2843. doi: 10.1001/archinte.160.18.2835. - DOI - PubMed
    1. Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1 Gaucher disease: The need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am. J. Hematol. 2007;82:697–701. doi: 10.1002/ajh.20908. - DOI - PubMed
    1. Thomas AS, Mehta AB, Hughes DA. Diagnosing Gaucher disease: An on-going need for increased awareness amongst haematologists. Blood Cells Mol. Dis. 2013;50:212–217. doi: 10.1016/j.bcmd.2012.11.004. - DOI - PubMed
    1. Mehta A, et al. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Mol. Genet. Metab. 2017;122:122–129. doi: 10.1016/j.ymgme.2017.08.002. - DOI - PubMed
    1. Mistry PK, et al. A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am. J. Hematol. 2011;86:110–115. doi: 10.1002/ajh.21888. - DOI - PMC - PubMed

Publication types

Substances